A Long-Term, Open-Label Safety and Tolerability Study of Lisdexamfetamine Dimesylate in Children Aged 4–5 Years with Attention-Deficit/Hyperactivity Disorder

OBJECTIVE: To evaluate the long-term safety and tolerability of lisdexamfetamine dimesylate (LDX) in preschool-aged children (4–5 years of age inclusive) diagnosed with attention-deficit/hyperactivity disorder (ADHD). METHODS: This phase 3 open-label study (ClinicalTrials.gov registry: NCT02466386)...

Descripción completa

Detalles Bibliográficos
Autores principales: Childress, Ann C., Lloyd, Eric, Johnson, Steven A., Gunawardhana, Lhanoo, Arnold, Valerie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc., publishers 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8971990/
https://www.ncbi.nlm.nih.gov/pubmed/35230142
http://dx.doi.org/10.1089/cap.2021.0138

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8971990/
https://www.ncbi.nlm.nih.gov/pubmed/35230142
http://dx.doi.org/10.1089/cap.2021.0138

Ejemplares similares